Immuno-oncology treatment pre-surgery safe and effective option for localized non-small cell lung cancer

New study data shows that the immuno-oncology drug, atezolizumab (marketed as Tecentriq) is a safe and effective treatment for stage IB-IIIB non-small cell lung cancer patients prior to lung cancer surgery. This is according to a new study led by researchers with The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard […]

Continue Reading

Nature-inspired peptide shows anti-tumor activity

An Austrian study demonstrates an anti-tumor effect of certain nature-derived cyclic peptides. The study, which has now been published internationally, not only demonstrates the inhibition of cell division by these peptides, but even their ability to cause cell death of cancer cells. Until now, one focus under investigation was the immunosuppressive effects of these peptides. […]

Continue Reading